The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback